September 27, 2016 7:27 PM ET


Company Overview of Akari Therapeutics, Plc

Executive Profile

Mark S. Cohen

Vice Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee, Akari Therapeutics, Plc
AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 2 different industries.

See Board Relationships


Mr. Mark S. Cohen serves as a Senior Partner and Chair of the Life Science Group at Pearl Cohen Zedek Latzer, LLP. Mr. Cohen served as the Executive Chairman of Akari Therapeutics, Plc (formerly Celsus Therapeutics Plc) from December 21, 2004 to September 2015. He has been the Vice Chairman of Akari Therapeutics since September 2015 and has been its Director since 2004. He is admitted to the New York and New Jersey bars in the United States and the Israel Bar, and a ...

Corporate Headquarters

24 West 40th Street
New York, New York 10018

United States

Phone: 646-350-0702
Fax: 646-843-9352

Board Members Memberships

Vice Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee


New York University
Rutgers, The State University of New Jersey
University Of Baltimore School Of Law

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$42,312
Total Calculated Compensation$230,842

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Akari Therapeutics, Plc, please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at